Clinical Trial Update: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

View source ↗

Summary

Clinical trial update for brentuximab vedotin (Recombinant) in relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• brentuximab vedotin (Recombinant) for IV Infusion (brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma | Status: COMPLETED | Results posted: 2019-05-06